Seeking Alpha

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on...

Peregrine Pharmaceuticals (PPHM +9.1%) moves up after its FQ1 beat estimates across the board on fewer than anticipated losses, despite a double digit Y/Y decline in total revenue. The stock soared on Friday, after the company said a recent Phase IIb trial of its lung cancer treatment bavituximab produced interim data showing statistically significant improvement in overall survival.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector